CURRICULUM VITAE

PERSONAL INFORMATION

Name	**CLAUDIA CECI**
E-mail address	**claudia.ceci@uniroma2.it**
Nationality	Italian
Date and place of birth	05/07/1985, VEROLI (FR)
Tax code	CCECLD85L45L780D

RESEARCH EXPERIENCE

Dates	**OCTOBER 2023 – TO DATE**
Name of employer	University of Rome "Tor Vergata"
Type of business or sector	Medical School, Department of Systems Medicine
Occupation or position held	Type B Researcher
Main activities and responsibilities	- Direct participation in every phase of the research project entitled "Preclinical evaluation of the efficacy and cardiac safety of a novel humanized anti-VEGFR-1 monoclonal antibody targeting the tumor and the tumor microenvironment: a preclinical assessment" (MUR – PRIN 2022).
	- Direct participation in every phase of the research project entitled ""MNESYS - A MULTISCALE INTEGRATED APPROACH TO THE STUDY OF THE NERVOUS SYSTEM IN HEALT AND DISEASE" (PNRR 2022).
	- International collaboration with i+HeALTH, European University Miguel de Cervantes, Valladolid, Spain and Faculty of Sport Sciences, Universidad Europea de Madrid, Madrid, Spain.

Dates	**OCTOBER 2022 – SEPTEMBER 2023**
Name of employer	UniCamillus International Medical University in Rome
Type of business or sector	Departmental Faculty of Medicine and Surgery
Occupation or position held	Type A Researcher
Main activities and responsibilities	- Direct participation in every phase of the research project entitled "Conjugation of a new humanized monoclonal antibody anti-VEGFR-1 with a cytotoxic compound".
	- International collaboration with i+HeALTH, European University Miguel de Cervantes, Valladolid, Spain and Faculty of Sport Sciences, Universidad Europea de Madrid, Madrid, Spain.

Dates	**DECEMBER 2021 – SEPTEMBER 2022**
Name of employer	University of Rome "Tor Vergata"
Type of business or sector	Medical School, Department of Systems Medicine, laboratory of Pharmacology
Occupation or position held	Research Grant entitled "Conjugation of a new humanized monoclonal antibody anti-VEGFR-1 with a cytotoxic compound" (Banca d'Italia – code F1-2021-0067, Prot. n. 0046066 del 08/10/2021 – Decree n. 2236/2021)
Main activities and responsibilities	Direct participation in every phase of the research project

Dates	**FEBRUARY 2018 – NOVEMBER 2021**
Name of employer	Biostilogit Pharmaceuticals Srl, Via Lilliano e Meoli, 78, 50012 Bagno a Ripoli (FI)
Type of business or sector	Medical School, Department of Systems Medicine, laboratory of Pharmacology, University of Rome "Tor Vergata"

Occupation or position held	Research collaboration.
Main activities and responsibilities	- Direct participation in every phase of the research project entitled "Antitumor activity of Ellagic acid derivatives".
	- Direct participation in every phase of the research project supported by the Italian Association for Cancer Research entitled "Validation and humanization of a novel anti-VEGFR-1 monoclonal antibody for malignant melanoma treatment" (AIRC, Investigator Grant IG 2017. N. 20353).
Dates	FEBRUARY 2016 – JULY 2016
Name of employer	University of Rome "Tor Vergata"
Type of business s or sector	Medical School, Department of Systems Medicine, laboratory of Pharmacology
Occupation or position held	Post-doctoral fellow "Antiproliferative and apoptotic activity of ellagic acid in bladder cancer cell models"; Rector's Decree n.3102, 02/11/2015.
Main activities and responsibilities	- Direct participation in every phase of the research project, in collaboration with Biostilogit Pharmaceuticals Srl, Via Lilliano e Meoli, 78, 50012 Bagno a Ripoli (FI).
	- Direct participation in every phase of the research project supported by the Italian Association for Cancer Research entitled "Targeting of VEGFR-1 and PARP-1 to reduce chemoresistance of glioblastoma and glioblastoma stem cells" (AIRC, Investigator Grant IG 2013 N. 14042).
Dates	DECEMBER 2014 - DECEMBER 2015
Name of employer	Biostilogit Pharmaceuticals Srl, Via Lilliano e Meoli, 78, 50012 Bagno a Ripoli (FI)
Type of business or sector	Medical School, Department of Systems Medicine, laboratory of Pharmacology, University of Rome "Tor Vergata"
Occupation or position held	Research collaboration.
Main activities and responsibilities	- Direct participation in every phase of the research project involving the characterization of the anticancer potential of ellagic acid.
	- Direct participation in every phase of the research project supported by the Italian Association for Cancer Research entitled "Targeting of VEGFR-1 and PARP-1 to reduce chemoresistance of glioblastoma and glioblastoma stem cells" (AIRC, Investigator Grant IG 2013 N. 14042).
Dates	DECEMBER 2011 – NOVEMBER 2014
Name of employer	University of Rome "Tor Vergata"
Type of business or sector	Medical School, Department of Systems Medicine, laboratory of Pharmacology
Occupation or position held	PhD student in Neuroscience
Main activities and responsibilities	Direct participation in every phase of the research project, from programming to laboratory activities.
Dates	NOVEMBER 2010 - APRIL 2011
Name of employer	University of Rome "Tor Vergata"
Type of business or sector	Medical School, Department of Neuroscience, laboratory of Pharmacology
Occupation or position held	Pre-doctoral fellow entitled "Epigenetic regulation and neural differentiation"; Rector's Decree n.3510, 6/10/2010
Main activities and responsibilities	Direct participation in every phase of the research project and laboratory activities.
Dates	NOVEMBER 2008 - MAY 2010
Name of employer	University of Rome "Tor Vergata"
Type of business or sector	Faculty of Mathematical, Physical and Natural Sciences, Department of Biology, laboratory of Cell and Developmental Biology
Occupation or position held	Graduating student for the degree (II level) in Cell and Molecular Biology
Main activities and responsibilities	Direct participation in every phase of the experimental thesis project and laboratory activities.

Dates	**MARCH 2007 - JUNE 2007**
Name of employer	University of Rome "Tor Vergata"
Type of business or sector	Faculty of Mathematical, Physical and Natural Sciences, Department of Biology, laboratory of Biochemistry
Occupation or position held	Graduating student for the degree (I level) in Cell and Molecular Biology
Main activities and responsibilities	Participation in laboratory activities.

EDUCATION AND TRAINING

Dates	**MAY 2023 - MAY 2034**
Title of qualification awarded	National Scientific Habilitation as Associate Professor of Pharmacology (BIO/14 – 05/G1)
Dates	**DECEMBER 2011 - MAY 2014**
Name and type of organisation providing education and training	University of Rome "Tor Vergata"; Medical School
Main subjects / professional abilities	Neuroscience, Developmental and cell biology
Title of qualification awarded	PhD in Neuroscience. Thesis title: "Nickel effect on neural differentiation"
Dates	**OCTOBER 2007 - MAY 2010**
Name and type of organisation providing education and training	University of Rome "Tor Vergata"; Faculty of Mathematical, Physical and Natural Sciences
Main subjects / professional abilities	Developmental and cell biology, biochemistry, genetic, molecular biology
Title of qualification awarded	Degree in Cellular and Molecular Biology, 110/110 *cum laude*
Level in national classification	Second level specialistic degree Thesis title: "Reticulon 1-C effect in chemotherapeutic treatment of human mammal adenocarcinoma MCF-7 cells"
Dates	**OCTOBER 2004 - OCTOBER 2007**
Name and type of organisation providing education and training	University of Rome "Tor Vergata"; Faculty of Mathematical, Physical and Natural Sciences
Main subjects / professional abilities	Genetic, biochemistry, cell biology, molecular biology
Title of qualification awarded	Degree in Cellular and Molecular Biology, 110/110 *cum laude*
Level in national classification	First level degree Thesis title: "Human DNA Topoisomerase I: analysis of mutations that could make the enzyme resistant to the antitumor drug camptothecin"
Dates	**SEPTEMBER 1999 - JUNE 2004**
Name and type of organization providing education and training	Scientific High School "Giovanni Sulpicio" in Veroli (Frosinone, Italy)
Title of qualification awarded	High School Diploma, 100/100

PARTICIPATION TO CONGRESS /COURSES/TRAINING EVENTS

- Participation in the 2nd Masterclass SIF-ECPG "Pharmacologists 2.0" - Innovative teaching and successful submissions, February 14th – 16th, 2024, organized by Pharmacology Italian Society;
- Participation in the "Leadership Master Class: Pharmacologists 2.0", June 13th – 15th 2023, organized by Pharmacology Italian Society;
- Participation in the practical training event "Animals used for scientific purpouses: Modules

3.2, 6.2 and 8", May 2023, organized by Istituto Zooprofilattico Sperimentale Lazio e Toscana "M. Aleandri" in collaboration with Lazio Region, University of Rome "Tor Vergata" and Istituto Superiore di Sanità, held in person with final assessment of learning;
- Participation in the theoretical training event "BIOLOGY AND MANAGEMENT OF LABORATORY ANIMALS, MODULES 3.1, 4, 5, 6.1, 7", July – November 2022, organized by Istituto Zooprofilattico Sperimentale Lazio e Toscana "M. Aleandri";
- Participation as a speaker at the "41st NATIONAL CONGRESS OF PHARMACOLOGY ITALIAN SOCIETY - THE SCIENTIFIC VALUE AND THE APPROPRIATE USE OF DRUG", with an oral communication entitled "Targeting PDGF-C to counteract melanoma invasiveness and resistance to BRAF inhibitors", from November 16th to November 19th 2022;
- Poster presentation entitled "Targeting of PDGF-C as a new strategy for counteracting melanoma metastatic potential and resistance to BRAF inhibitors" at the "8th EUROPEAN VIRTUAL CONGRESS OF PHARMACOLOGY (EPHAR 2021) – From Great Science to better Medicine for Europe", from December 6th 2021 to December 8th 2021;
- Participation in the training course on access to the use of animal experimentation service facilities, organized by Protection and Prevention Service of University of Rome "Tor Vergata", January 2015;
- Participation in the training course on safety and health in the workplace and chemical risk, organized by Protection and Prevention Service of University of Rome "Tor Vergata", April 2014;
- Participation in the training and information course on prevention in the use of radiogenic substances, organized by Protection and Prevention Service of University of Rome "Tor Vergata", October 2010.

TEACHING EXPERIENCE AND ACADEMIC ASSIGNMENTS

- "Special Pharmacology and Therapy - Module I" Course Owner, Degree Course in Pharmacy, University of Rome "Tor Vergata" (5 CFU, a.y. 2018/2019, 2019/2020, 2020/2021, 2021/2022, 2022/2023, 2023/2024).
- Lecturer of lessons concerning "Cellular and Molecular Pharmacology" and "Pharmacogenomics", Degree Course in Pharmacy, Cyprus International University, Summer Semester a.y. 2021/2022 and 2022/2023.
- "Pharmaceutical Toxicology and galenic Pharmacology" Course Owner, Degree Course in Biomedical Laboratory Techniques, UniCamillus International Medical University in Rome (3 CFU, a.y. 2022/2023).
- "Pharmacology" Course Owner, Degree Course in Medicine and Surgery, UniCamillus International Medical University in Rome (5 CFU, a.y. 2020/2021, 2021/2022, 2022/2023).
- "Pharmacology" Course Owner, Degree Course in Midwifery, UniCamillus International Medical University in Rome (1 CFU, a.y. 2019/2020, 2020/2021, 2021/2022, 2022/2023).
- Co-relator of Experimental and Theoretical Thesis, Degree Course in Pharmacy, University of Rome "Tor Vergata".
- Member of the Students-Professors Joint Committee of UniCamillus International Medical University in Rome.

PERSONAL SKILLS AND COMPETENCES

MOTHER TONGUE

ITALIAN

OTHER LANGUAGES

ENGLISH

Reading	C1
Writing	C1
Oral expression	B2

FRENCH

Reading	A2

Writing	A2
Oral expression	A2

TECHNICAL SKILLS AND COMPETENCES

- EUKARYOTIC CELL CULTURES
- TREATMENT WITH ANTITUMOR DRUGS AND VIABILITY ASSAYS
- BACTERIAL CULTURES AND TRANSFORMATION
- DNA AND PROTEIN EXTRACTION
- WESTERN BLOT
- IMMUNOFLUORESCENCE
- IMMUNOPRECIPITATION
- PCR
- ELISA
- CELL TRANSFECTION
- CELL INVASION AND MIGRATION ASSAYS
- PRECLINICAL CHARACTERIZATION IN MURINE MODELS OF ANTICANCER DRUGS AND COMPOUNDS FROM THE DIET ANTIPROLIFERATIVE ACTIVITY

EDITORIAL ACTIVITY

Since September 2020, Editorial Board Member of scientific journal "Chemotherapy" (Kanger)

MEMBERSHIP IN SCIENTIFIC SOCIETIES

Since June 2021, Member of Pharmacology Italian Society

HONORS AND AWARDS

AWARD Pharmacology Italian Society - Farmindustria 2022

PATENTS

Co-author (5%) of the patent entitled "Microsfere di idrogeli di polimeri polisaccaridici contenenti cellule neurali secernenti dopamina, procedimento per la loro preparazione e loro usi in campo medico", number RM2013A000572.

Rome, April 20th, 2024

PUBLICATIONS

Garufi A, Pistritto G, **Ceci C**, Di Renzo L, Santarelli R, Faggioni A, Cirone M, D'Orazi G. Targeting COX-2/PGE(2) pathway in HIPK2 knockdown cancer cells: impact on dendritic cell maturation. PLoS One. 2012;7(11).

Pistritto G, Papaleo V, Sanchez P, **Ceci C**, Barbaccia ML. Divergent modulation of neuronal differentiation by Caspase-2 and -9. PLoS One. 2012;7(5).

Ceci C, Barbaccia ML, Pistritto G. A not cytotoxic nickel concentration alters the expression of neuronal differentiation markers in NT2 cells. Neurotoxicology. 2015;47:47-53.

Graziani G, Artuso S, De Luca A, Muzi A, Rotili D, Scimeca M, Atzori MG, **Ceci C**, Mai A, Leonetti C, Levati L, Bonanno E, Tentori L, Caccuri AM (2015). A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib. Biochem Pharmacol. 95(1):16-27.

Pistritto G, Trisciuoglio D, **Ceci C**, Garufi A, D'Orazi G. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY). 2016 (4):603-19.

Ceci C, Tentori L, Atzori MG, Lacal PM, Bonanno E, Scimeca M, Cicconi R, Mattei M, de Martino MG, Vespasiani G, Miano R, Graziani G (2016). Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth. Nutrients 8(11).

Atzori MG, Tentori L, Ruffini F, **Ceci C**, Lisi L, Bonanno E, Scimeca M, Eskilsson E, Daubon T, Miletic H, Ricci Vitiani L, Pallini R, Navarra P, Bjerkvig R, D'Atri S, Lacal PM, Graziani G. The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells. J Exp Clin Cancer Res. 2017; 36(1):106.

Cacciotti I, **Ceci C**, Bianco A, Pistritto G. Neuro-differentiated Ntera2 cancer stem cells encapsulated in alginate beads: First evidence of biological functionality. Mater Sci Eng C Mater Biol Appl. 2017;81:32-38.

Atzori MG, Tentori L, Ruffini F, **Ceci C**, Bonanno E, Scimeca M, Lacal PM, Graziani G. The Anti-Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody D16F7 Inhibits Glioma Growth and Angiogenesis In Vivo. J Pharmacol Exp Ther. 2018; 364(1):77-86.

Ceci C, Lacal PM, Tentori L, De Martino MG, Miano R, Graziani G. Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid. Nutrients. 2018; 10(11).

Atzori MG, **Ceci C**, Ruffini F, Trapani M, Barbaccia ML, Tentori L, D'Atri S, Lacal PM, Graziani G. Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib. J. Cell. Mol. Med. 2020, 24, 465-475.

Ceci C, Atzori MG, Lacal, PM, Graziani, G. Role of VEGFs/VEGFR-1 signaling and its inhibition in modulating tumor invasion: experimental evidence in different metastatic cancer models. Int J Mol Sci. 2020; 21(4):1338.

Ceci C, Graziani G, Faraoni I, Cacciotti I. Strategies to improve ellagic acid bioavailability: from natural or semisynthetic derivatives to nanotechnological approaches based on innovative carriers. Nanotechnology. 2020; 31(38): 382001.

Ceci C, Atzori MG, Lacal PM, Graziani G. Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma. Cancers (Basel). 2020;12(11):3401.

Ceci C, Lacal PM, Graziani G. Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential. Pharmacol Ther. 2022;236:108106.

Atzori MG, **Ceci C**, Ruffini F, Scimeca M, Cicconi R, Mattei M, Lacal PM, Graziani G. The Anti-Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) D16F7 Monoclonal Antibody Inhibits

Melanoma Adhesion to Soluble VEGFR-1 and Tissue Invasion in Response to Placenta Growth Factor. Cancers (Basel). 2022 Nov 14;14(22):5578.

García-Chico C, López-Ortiz S, Peñín-Grandes S, Pinto-Fraga J, Valenzuela PL, Emanuele E, **Ceci C**, Graziani G, Fiuza-Luces C, Lista S, Lucia A, Santos-Lozano A. Physical Exercise and the Hallmarks of Breast Cancer: A Narrative Review. Cancers (Basel). 2023 Jan 3;15(1):324.

Ruffini F**, Ceci C**, Atzori MG, Caporali S, Levati L, Bonmassar L, Cappellini GCA, D'Atri S, Graziani G, Lacal PM. Targeting of PDGF-C/NRP-1 autocrine loop as a new strategy for counteracting the invasiveness of melanoma resistant to braf inhibitors. Pharmacol Res. 2023 Apr 29;192:106782.

Ceci C, García-Chico C, Atzori MG, Lacal PM, Lista S, Santos-Lozano A, Graziani G, Pinto-Fraga J. Impact of physical exercise on melanoma hallmarks: current status of preclinical and clinical research. Journal of Cancer. 2023.

Ceci C, Lacal PM, Barbaccia,ML, Mercuri,NB, Graziani G, Ledonne A, The VEGFs/VEGFRs system in Alzheimer's and Parkinson's diseases: Pathophysiological roles and therapeutic implications. Pharmacol Res. 2024; 201:107101.

Rome, April 20th, 2024